Anika Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $277.36M
- P/E (TTM)
- –
- Dividend yield
- –
About Anika Therapeutics
Surgical & Medical Instruments & Apparatus, SIC 3841
Anika Therapeutics, Inc. develops and commercializes medical therapies focused on osteoarthritis pain management and regenerative solutions for early intervention orthopedics. Utilizing proprietary hyaluronic acid technology, the company offers pain relief injections such as Orthovisc, Monovisc, and Cingal, alongside regenerative orthopedic implants and bone substitutes including the Integrity system, Hyalofast, and Tactoset. It also supplies non-orthopedic legacy lines, comprising ophthalmic aids, anti-adhesion barriers, and equine treatments. Anika serves healthcare providers across office practices, hospital operating rooms, and ambulatory surgery centers through direct sales, commercial partnerships, and third-party distributors.
The company manufactures its hyaluronic acid product lines at a centralized production facility located in Bedford, Massachusetts. Internationally, its therapies reach global markets through worldwide distributor agreements, with products such as Cingal distributed in more than 50 countries and Hyalofast available across more than 30 nations throughout Europe, South America, and Asia.
Summary of the business section of Anika Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Anika Therapeutics, Inc.
- Founded
- 1992
- Headquarters
- Bedford, MA
- Address
- 32 Wiggins Avenue 01730
- Phone
- (781) 457-9000
- Employees
- 235, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ANIK
- Exchange
- Nasdaq
- IPO date
- May 3, 1993
- Shares outstanding
- 13M, Jul 24, 2026
- Public float
- $147.34M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 898437
- CUSIP
- 035255108
- ISIN
- US0352551081
- LEI
- 529900R9LS3Z0O6QH455
- EIN
- 04-3145961
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stephen D. Griffin | President and CEO, Director | 49,742 |
| Ian McLeod | SVP, CAO & Treasurer | 24,888 |
| David Colleran | EVP, General Counsel, Corp Sec | 67,570 |
| Anne Nunes | SVP, Chief Operations Officer | 21,722 |
| Gary P. Fischetti | Director | 54,015 |
| Joseph H. Capper | Director | 30,805 |
| Sheryl L. Conley | Director | 52,970 |
| John B. Henneman Iii | Director | 65,273 |
| Stephen Richard | Director | 58,273 |
| Cheryl R. Blanchard | Director | 282,634 |
| William R. Jellison | Director | 23,103 |
| Glenn R. Larsen | Director | 50,258 |
| Susan L. N. Vogt | Director | 50,213 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.89M | $2.08M | $1.34M | $21 | $120 |
| FY2024 | $5.10M | $2.53M | $1.81M | $36 | $91 |
| FY2024 Dr Blanchard | $5.10M | $2.53M | $1.81M | $36 | $91 |
| FY2023 | $4.46M | $1.87M | $1.41M | $50 | $92 |
| FY2023 Blanchard | $4.46M | $1.87M | $1.41M | $50 | $92 |
| FY2023 Dr Blanchard | $4.46M | $1.87M | $1.41M | $50 | $92 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 235 full-time employees in the United States and Europe.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 11, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 31, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 3, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 24, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 5, 2017 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 28, 2017 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 6, 2010 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 7, 2008 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 7, 1998 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 27, 1996 | Name change | Name changed from ANIKA RESEARCH INC to ANIKA THERAPEUTICS INC |